Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
Sarepta Therapeutics (NASDAQ:SRPT) has launched the 8th Annual Route 79 Duchenne Scholarship Program for the 2025-2026 academic year. The program will award academic scholarships of up to $5,000 to as many as 20 individuals living with Duchenne muscular dystrophy and 5 siblings of those affected.
Applications will be accepted until May 30, 2025, with recipients notified before August 2025. Eligible applicants must be accepted to or enrolled in an accredited U.S. college, university, or trade school. The selection process is conducted by an independent committee, with awards distributed for fall 2025 enrollment.
The scholarship program, named after the 79 exons of the dystrophin gene, allows recipients to receive awards up to four times. Selection is made without consideration of whether applicants use Sarepta products or therapies.
Sarepta Therapeutics (NASDAQ:SRPT) ha lanciato l'8° Programma di Borse di Studio Route 79 Duchenne per l'anno accademico 2025-2026. Il programma assegnerà borse di studio accademiche fino a $5,000 a un massimo di 20 individui affetti da distrofia muscolare di Duchenne e a 5 fratelli di coloro che sono colpiti.
Le domande saranno accettate fino al 30 maggio 2025, con i destinatari che saranno notificati prima di agosto 2025. I candidati idonei devono essere stati accettati o iscritti a un college, università o scuola professionale accreditata negli Stati Uniti. Il processo di selezione è condotto da un comitato indipendente, con le borse distribuite per l'iscrizione all'autunno 2025.
Il programma di borse di studio, intitolato ai 79 esoni del gene della distrofina, consente ai destinatari di ricevere premi fino a quattro volte. La selezione avviene senza considerare se i candidati utilizzano prodotti o terapie Sarepta.
Sarepta Therapeutics (NASDAQ:SRPT) ha lanzado el 8° Programa Anual de Becas Route 79 Duchenne para el año académico 2025-2026. El programa otorgará becas académicas de hasta $5,000 a un máximo de 20 personas que viven con distrofia muscular de Duchenne y a 5 hermanos de los afectados.
Las solicitudes se aceptarán hasta el 30 de mayo de 2025, con los beneficiarios notificados antes de agosto de 2025. Los solicitantes elegibles deben estar aceptados o matriculados en un colegio, universidad o escuela técnica acreditada en EE. UU. El proceso de selección es llevado a cabo por un comité independiente, con los premios distribuidos para la inscripción en otoño de 2025.
El programa de becas, nombrado en honor a los 79 exones del gen de la distrofina, permite a los beneficiarios recibir premios hasta cuatro veces. La selección se realiza sin considerar si los solicitantes utilizan productos o terapias de Sarepta.
세렙타 테라퓨틱스 (NASDAQ:SRPT)가 2025-2026 학년도에 대한 제8회 Route 79 듀센 장학금 프로그램을 시작했습니다. 이 프로그램은 듀센 근육 이영양증에 걸린 최대 20명과 그 영향을 받는 사람의 형제자매 5명에게 최대 $5,000의 학업 장학금을 수여합니다.
신청서는 2025년 5월 30일까지 접수되며, 수혜자는 2025년 8월 이전에 통보됩니다. 자격이 있는 신청자는 미국의 공인 대학, 대학교 또는 직업학교에 입학하거나 등록되어 있어야 합니다. 선정 과정은 독립적인 위원회에 의해 진행되며, 장학금은 2025년 가을 등록을 위해 배분됩니다.
79개의 돌연변이 유전자를 기리기 위해 명명된 이 장학금 프로그램은 수혜자가 최대 4회까지 장학금을 받을 수 있도록 합니다. 선정은 신청자가 세렙타의 제품이나 치료를 사용하는지 여부와 관계없이 이루어집니다.
Sarepta Therapeutics (NASDAQ:SRPT) a lancé le 8ème Programme de Bourses d'Études Route 79 Duchenne pour l'année académique 2025-2026. Le programme attribuera des bourses d'études académiques allant jusqu'à $5,000 à un maximum de 20 personnes vivant avec la dystrophie musculaire de Duchenne et à 5 frères et sœurs de ceux qui sont touchés.
Les candidatures seront acceptées jusqu'au 30 mai 2025, avec notification des bénéficiaires avant août 2025. Les candidats éligibles doivent être acceptés ou inscrits dans un collège, une université ou une école professionnelle accréditée aux États-Unis. Le processus de sélection est mené par un comité indépendant, avec des bourses attribuées pour l'inscription à l'automne 2025.
Le programme de bourses, nommé d'après les 79 exons du gène de la dystrophine, permet aux bénéficiaires de recevoir des prix jusqu'à quatre fois. La sélection est effectuée sans tenir compte de l'utilisation des produits ou des thérapies de Sarepta par les candidats.
Sarepta Therapeutics (NASDAQ:SRPT) hat das 8. jährliche Route 79 Duchenne Stipendienprogramm für das akademische Jahr 2025-2026 ins Leben gerufen. Das Programm vergibt akademische Stipendien von bis zu $5,000 an bis zu 20 Personen mit Duchenne-Muskeldystrophie und 5 Geschwister von Betroffenen.
Die Bewerbungen werden bis zum 30. Mai 2025 angenommen, und die Empfänger werden vor August 2025 benachrichtigt. Berechtigte Bewerber müssen an einem akkreditierten College, einer Universität oder einer Berufsschule in den USA angenommen oder eingeschrieben sein. Der Auswahlprozess wird von einem unabhängigen Ausschuss durchgeführt, die Stipendien werden für die Einschreibung im Herbst 2025 vergeben.
Das Stipendienprogramm, das nach den 79 Exonen des Dystrophin-Gens benannt ist, ermöglicht es den Empfängern, bis zu viermal Auszeichnungen zu erhalten. Die Auswahl erfolgt ohne Berücksichtigung, ob die Bewerber Produkte oder Therapien von Sarepta verwenden.
- None.
- None.
– Applications for the 2025-2026 academic year will be accepted until May 30, 2025
– Scholarships will be awarded to up to 20 individuals living with Duchenne muscular dystrophy and up to five siblings of individuals living with Duchenne
“In the past decade, there have been significant advancements in the treatment of Duchenne muscular dystrophy that have brought a different kind of future for individuals living with Duchenne and their families,” said Diane Berry, Ph.D., executive vice president and Chief Global Policy & Advocacy Officer, Sarepta. “The Route 79 Duchenne Scholarship Program celebrates these new possibilities with our Duchenne community, supporting their educational aspirations as young adults. On behalf of Sarepta and the selection committee, we’d like to invite students who live with Duchenne or have a sibling who lives with Duchenne to apply as they pursue their educational goals for the year. We’re looking forward to meeting this year’s applicants and paving the way for these Route 79 scholars as they begin the next chapter of their academic journeys.”
To apply for a scholarship through the Route 79 program, applicants must be accepted to or enrolled in an accredited college or university, or a trade, technical or vocational school located in
Applications will be accepted until Friday, May 30, 2025, at 11:59 p.m. PDT. Recipients will be notified prior to August 2025, and awards will be distributed directly to the school, college or university in time for fall 2025 enrollment. Students may learn more about the program, application criteria, and how to apply by visiting Sarepta.com/route79.
About Route 79, The Duchenne Scholarship Program
The Route 79 program is designed to help students living with Duchenne and siblings of individuals living with Duchenne pursue their post-secondary educational goals. Scholarship recipients are chosen by an independent committee of Duchenne community members based on an applicant’s academic and community involvement, personal essay, and recommendation letter. The underlying cause of Duchenne is a difference in the gene coding for dystrophin. Dystrophin is an essential protein that plays a pivotal role in muscle structure, function and preservation. The numerical significance of the scholarship’s name, Route 79, ties to the 79 exons of the dystrophin gene. For more information, visit sarepta.com/route79.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.com or follow us on LinkedIn, X, Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250228553852/en/
Investor Contact:
Ian Estepan
617-274-4052
iestepan@sarepta.com
Media Contacts:
Tracy Sorrentino
617-301-8566
tsorrentino@sarepta.com
Kara Hoeger
617-710-3898
KHoeger@sarepta.com
Source: Sarepta Therapeutics, Inc.
FAQ
What is the maximum scholarship amount offered by Sarepta's Route 79 Program for 2025-2026?
How many scholarships will SRPT award in the Route 79 Program for 2025-2026?
When is the application deadline for Sarepta's 2025 Route 79 Scholarship Program?
How many times can students receive the SRPT Route 79 Scholarship?
